Clinical Breast Cancer

Long term follow-up of the randomized MetaspHER study comparing intravenous versus subcutaneous trastuzumab in patients with HER2-positive metastatic breast cancer

ESMO Open

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure

Scientific Reports

Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression

2023 ASCO Annual Meeting Abstract

Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer

https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.1014

Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study

2023 ASCO Annual Meeting Abstract

HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer

2023 ASCO Annual Meeting Abstract

Pertuzumab retreatment in patients with HER2-positive locally advanced/metastatic breast cancer: Overall survival results of a phase III randomized trial (JBCRG-M05: PRECIOUS)

2023 ASCO Annual Meeting Abstract

Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial

2023 ASCO Annual Meeting Abstract

An age-specific pooled analysis of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC) from DESTINY-Breast01, -02, and -03

JCO Oncology Practice

Real-world perspectives and practices for pneumonitis/interstitial lung disease associated with trastuzumab deruxtecan use in human epidermal growth factor receptor 2–expressing metastatic breast cancer